Explore Intellia Therapeutics, Inc.'s outlook after Phase 3 trial concerns. See how FDA decisions may impact CRISPR therapy ...

Despite a challenging CASGEVY launch, high cash burn, and an almost 10% YTD share count growth, CRISPR’s pipeline breadth and ...

The gene editing market is experiencing significant growth, with a projected annual growth rate (CAGR) of 16-18% in the coming years. This expansion is fueled by breakthroughs in gene-editing ...

New gene-editing tools – most notably the Nobel Prize-winning CRISPR-Cas9 – allow targeted tweaks to a crop’s genome, ...

CorriXR Therapeutics, an oncology-focused biotherapeutics company pioneering a ground-breaking gene editing platform technology, InhaTarget Therapeutics, a company dedicated to the early development ...

Comparing the genomes of snakes with distinct coloration patterns pinpointed the genetic variants that contribute to these ...

When blood cancer in children progresses particularly aggressively, it is often due to a genetic defect: a gene fusion, such ...

From custom gene editing to a discovery that could help stop pancreatic cancer before it starts, these advances offer a ...

Centella asiatica, also known as gotu kola, is widely valued for its triterpenoid saponins, especially asiaticoside and ...

For years, Yale researchers David Breslow and Mustafa Khokha have worked together with a similar challenge in their ...

A research team at the Wuhan University of Science and Technology (WUST) has recently developed a new targeted delivery ...